# **Equitas Small Finance Bank**

Refer to important disclosures at the end of this report

# Delivers strong earnings beat; robust liability profile

- Despite the sharp drop in NIM, Equitas SFB reported strong PAT of Rs1.1bn (vs. est. of Rs0.5bn), up 162% yoy, mainly driven by higher fees and contained provisions, partly offset by higher opex. The headline GNPA improved to 3.7% from pro forma GNPA of 4.2% in Q3. However, the restructuring pool has inched up to 2.6% of loans.
- Gross credit growth moderated and was up 17% yoy/3% qoq due to subdued growth in the MFI segment where the bank remains cautious. The share of MFI has now fallen to 18% of loans. Deposit growth has been far stronger, with CASA ratio now being the highest among SFBs at 34% due to focused approach.
- Overall collection/billing efficiency for Mar'21 improved to 109%/91% from 105%/89% in Q3, mainly due to healthy improvement in the VF portfolio (98.9% vs. 96% in Q3). The second Covid wave has impacted business operations a bit with some employees being unwell. However, the impact on growth/asset quality should be limited and manageable.
- The bank steered well through the pandemic and emerged far stronger on the liability front with limited asset-quality impact, delivering healthy RoA/RoE of 1.8%/13% in FY21, which we expect now to improve to 2%/15% by FY23E. We retain Buy and raise TP from Rs52 to Rs74, valuing the bank at 1.9x FY23E ABV (1.5x earlier). On Equitas Holding too, we maintain Buy with a TP of Rs152 (assuming a 25% holdco discount).

**Deposit retailization picks up pace but NIMs shrink qoq:** Gross credit growth moderated in the quarter and was up 17% yoy/3% qoq (albeit on a higher base) to Rs179bn, due to subdued growth in the MFI segment as bank continues its cautious stance on MFI. Disbursements, though up 5.4% yoy, remained low in MFI, and the book now contributes 18% of the portfolio, in line with the bank's strategy to diversify the loan book away from volatile MFI. Deposit growth remained healthy at 52% yoy/3% qoq, mainly driven by strong 174% yoy/45% qoq growth in SA, stemming from the bank's increased focus on retailization of deposits. Accordingly, CASA ratio improved sharply by 924bps to 34%, while Retail TD grew 54% yoy/7% qoq. However, NIM dropped 90bps qoq to 7.6%, mainly due to NPA recognition, interest wavier and lower LDR.

**Improved asset quality but a higher contingent buffer would have been ideal:** The headline GNPA ratio improved to 3.7% from pro forma GNPA of 4.2% in Q3, mainly due to heavy write-offs in the MFI portfolio (Rs1.7bn). The restructured pool inched up qoq to 2.6% of loans from ~2% in Q3. Overall collection/billing efficiency for Mar'21 improved to 109%/91%, compared to 105%/89% in Q3, mainly due to healthy improvement in the VF portfolio (98.9% vs. 96% in Q3). Collection efficiency for SBL too remained healthy at 99.6%, while for MFI at 98.7%. The bank has consumed Rs1.7bn of contingent provisions as NPA recognition begins and is left with a buffer amounting to ~15bps of loans in addition to a reasonable management overlay (provisions over and above IRAC norms) of Rs1.5bn (89bps of loans). We believe that a higher contingent buffer running into a second Covid wave would have been ideal.

**Outlook and valuation:** We like Equitas for its healthy asset diversification away from the volatile MFI space, best CASA/liability profile among listed SFBs, capital comfort and reasonable valuations. The overhang of promoter stake dilution is largely over with the RBI's IWG recommendations, while the transition to Universal Banking License from relatively restrictive SFB license should be a long-term positive for the bank. We retain Buy rating on Equitas SFB with a TP of Rs74, valuing the bank now at 1.9x FY23E ABV (1.5x earlier), factoring in better return ratios and growth trajectory. On Equitas Holding too, we retain Buy with a revised TP of Rs152 (assuming a 25% holdco discount). Key risks: Higher-than-expected NPAs due to the second Covid wave, loss of momentum in CASA flow and management attrition.

Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-Banks (page 8)

# **Financial Snapshot (Standalone)**

	• •				
(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Net income	17,777	22,152	26,584	31,649	38,610
Net profit	2,438	3,857	5,095	6,503	8,391
EPS (Rs)	2.4	3.5	4.5	5.7	7.4
ABV (Rs)	24.7	29.1	32.4	38.1	45.6
RoA (%)	1.4	1.8	1.9	2.0	2.0
RoE (%)	9.8	12.6	14.0	15.4	16.9
PE (x)	23.4	15.8	12.4	9.7	7.5
P/ABV	2.1	1.8	1.6	1.4	1.2

Source: Company, Emkay Research



СМР	Target Price
<b>Rs 56</b> as of (April 29, 2021)	Rs 74 (▲) <sup>12 months</sup>
Rating	Upside
BUY (∎)	33.3 %

## Change in Estimates

EPS Chg FY22E/FY23E	(%)	14.7/3.3							
Target Price change (%)		NA							
Target Period (Months)		12							
Previous Reco									
Emkay vs Consensus									
EPS Estimates									
	FY22E	FY23E							
Emkay	4.5	5.7							
Consensus	4.6	6.1							
Mean Consensus TP (12	2M)	Rs 66							
Stock Details									
Bloomberg Code	EQU	ITASB IN							
Face Value (Rs)		10							
Shares outstanding (mn)	)	1,139							
52 Week H/L		68 / 30							
M Cap (Rs bn/USD bn)		63 / 0.85							
Daily Avg Volume (nos.)		1,855,687							
Daily Avg Turnover (USS	\$mn)	1.4							


#### Shareholding Pattern Nov '20

•	
Promoters	82.1%
FIIs	1.3%
DIIs	10.4%
Public and Others	6.3%

#### **Price Performance**

(%)	1M	3M	6M	12M
Absolute	(8)	41	68	-
Rel. to Nifty	(8)	31	34	-

### Relative price chart



Equitas Small Finance Bank (LHS) \_\_\_\_\_\_ Rel to Nifty (RHS)

Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

# Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Neelam Bhatia

neelam.bhatia@emkayglobal.com

+91 22 6612 1262


# Mayank Agarwal

mayank.agarwal@emkayglobal.com

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


# Story in Charts

Exhibit 1: Net advances growth remained stable while strong deposits momentum continued




Source: Company, Emkay Research

Exhibit 3: Disbursements inching back to pre-Covid levels



Source: Company, Emkay Research

# Exhibit 5: Slippages optically look high due to the removal of SC standstill on NPA recognition




Source: Company, Emkay Research

Source: Company, Emkay Research

# Exhibit 4: Strong growth in SA, supported by reduction of bulk deposits led to a sharp improvement in CASA qoq

■MFL ■SBL ■VF ■MSE Loans ■Corporate ■Others



Source: Company, Emkay Research

Exhibit 6: GNPA at 3.7% is lower compared to pro forma 4.2% on higher write-offs




Exhibit 2: Share of MFI further declined to 18% of the book, in line with management's strategy to trim volatile MFI

18%

44%

4%1%

7%

25%

Source: Company, Emkay Research

# Exhibit 7: Collection efficiency (%)

	· <b>J</b> (· · ·)			
Particulars	X Bucket Collection	X Bucket Collection	X Bucket Collection	
r ai liculai s	Efficiency	Efficiency	Efficiency	
	Mar-21	Dec-20	Feb-20	
Small Business Loans	99.60%	99.05%	99.41%	
Vehicle Finance	98.85%	95.72%	96.50%	
Micro Finance	98.70%	98.30%	98.50%	
Source: Company Emkay Pese	arch			

Source: Company, Emkay Research

### Exhibit 8: Actual vs. Estimates (Q4FY21)

Rs mn	Actuals	Estimates	% Variation	Comments
		Emkay	Emkay	
Net income	6,270	5,565	13%	Higher fee income led to a beat
PPOP	2,498	1,986	26%	Net income supported PPOP
PAT	1,129	524	116%	Contained provisions led to a beat

Source: Company, Emkay Research

# Exhibit 9: Quarterly Summary

Rs (mn)	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21	YoY (%)	QoQ (%)	FY21E	FY22E	YoY (%)
Interest Earned	7,258	7,210	7,975	8,572	8,183	13	-5	31,941	38,503	21
Interest Exp	3,019	3,170	3,363	3,734	3,698	22	-1	13,970	16,231	16
Net Interest Income	4,239	4,040	4,612	4,839	4,486	6	-7	17,971	22,273	24
Global NIMs (reported)	9.11	8.63	9.02	8.47	7.57	-154bps	-90bps	8.5	8.6	3bps
Non-interest Income	736	300	637	1,463	1,784	142	22	4,181	4,311	3
Operating Expenses	3,092	2,880	3,053	3,551	3,771	22	6	13,255	15,364	16
Pre Provisioning Profit	1,884	1,460	2,197	2,750	2,498	33	-9	8,897	11,220	26
Provision & Contingencies	1,299	680	839	1,261	970	-25	-23	3,750	4,411	18
РВТ	585	780	1,358	1,490	1,529	161	3	5,147	6,808	32
Income Tax Expense (Gain)	154	180	328	383	400	159	5	1,290	1,714	33
Net Profit/(Loss)	431	600	1,030	1,107	1,129	162	2	3,857	5,095	32
Gross NPA (%)	2.72	2.68	2.48	2.27	3.73	101bps	146bps	3.73	3.36	-37bps
Net NPA (%)	1.66	1.39	1.03	0.67	1.58	-8bps	91bps	1.58	1.37	-21bps
Deposits (Rs in bn)	108	118	129	159	164	52	3	164	210	28
Net Advances (Rs in bn)	137	144	159	168	168	23	0	168	211	25

Source: Company, Emkay Research

# Exhibit 10: Revision in estimates

Y/E Mar (Rs mn)		FY22E			FY23E		FY24E
	Earlier	Revised	% change	Earlier	Revised	% change	Introduced
Net income	25,859	26,584	2.8%	31,426	31,649	0.7%	38,610
PPOP	10,801	11,220	3.9%	13,362	13,474	0.8%	16,716
PAT	4,488	5,095	13.5%	6,293	6,503	3.3%	8,391
EPS (Rs)	3.9	4.5	14.7%	5.5	5.7	3.8%	7.4
BV (Rs)	33	34	2.6%	39	40	2.8%	47

Source: Emkay Research

We have revised our earnings estimates for FY22/23E by 14%/3%, factoring in better growth trajectory, asset-quality trends and lower credit cost.

### Exhibit 11: Key assumptions

	FY21A	FY22E	FY23E	FY24E
Loan Growth %	22.6	25.2	30.2	25.1
Deposit Growth %	51.9	28.3	31.3	27.8
NIM %	8.5	8.6	8.4	8.3
GNPA %	3.7	3.4	2.9	2.6
Credit Cost %	2.2	2.1	1.7	1.5

Source: Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Equitas Small Finance Bank (EQUITASB IN)

# Exhibit 12: Key trends and ratios

	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21
Loans (Rs bn)	116	120	130	137	137	144	159	168	168
-Growth % (YoY )	48.7	36.4	38.4	29.8	18.6	19.7	22.9	22.7	22.6
-Growth % (QoQ)	9.8	3.7	7.8	5.7	0.3	4.7	10.7	5.6	0.2
Liability Profile									
Deposit	90,067	91,330	100,250	104,932	107,884	117,870	129,006	158,620	163,920
Deposit (Rs bn)	90	91	100	105	108	118	129	159	164
-Growth % (YoY )	62.3	34.8	44.1	32.6	19.8	29.1	28.7	51.2	51.9
-Growth % (QoQ)	13.8	1.4	9.8	4.7	2.8	9.3	9.4	23.0	3.3
Asset Quality (%)									
GNPA	2.5	2.8	2.9	2.9	2.7	2.7	2.5	2.3	3.7
NNPA	1.4	1.7	1.8	1.7	1.7	1.4	1.0	0.7	1.6
PCR	43.4	44.1	43.8	43.5	45.2	48.8	50.2	66.2	58.6
Slippages (Rs mn)	644	794	1,146	1,272	881	154	229	365	5,146
Slippages - annualized (%)	3.3	3.6	4.9	4.8	3.0	0.5	0.7	1.1	15.0
<b>ROE Decomposition %</b>									
NII	8.5	8.3	8.3	8.6	9.0	8.0	8.4	8.0	7.2
Other Income	1.9	1.5	1.5	1.9	1.6	0.6	1.2	2.4	2.8
Орех	7.1	6.8	6.8	7.0	6.5	5.7	5.6	5.9	6.0
PPOP	3.2	3.0	3.0	3.5	4.0	2.9	4.0	4.6	4.0
Provisioning Cost	0.7	0.8	1.1	0.9	2.7	1.4	1.5	2.1	1.5
PBT	2.6	2.3	2.0	2.6	1.2	1.6	2.5	2.5	2.4
Tax	0.9	0.8	0.8	0.5	0.3	0.4	0.6	0.6	0.6
ROA	1.7	1.5	1.1	2.1	0.9	1.2	1.9	1.8	1.8
Leverage (x)	6.8	7.0	7.2	6.6	6.9	7.2	7.5	7.4	7.4
ROE	11.6	10.2	8.1	13.9	6.3	8.6	14.2	13.5	13.3

Source: Company, Emkay Research

# Key Financials (Standalone)

# **Income Statement**

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Net interest income	14,954	17,971	22,273	26,881	33,328
Other income	2,824	4,181	4,311	4,768	5,282
Fee income	210	1,590	1,829	2,194	2,589
Net income	17,777	22,152	26,584	31,649	38,610
Operating expenses	11,801	13,255	15,364	18,174	21,895
Pre provision profit	5,977	8,897	11,220	13,474	16,716
PPP excl treasury	5,943	8,465	11,004	13,280	16,521
Provisions	2,466	3,750	4,411	4,785	5,502
Profit before tax	3,511	5,147	6,808	8,690	11,214
Тах	1,073	1,290	1,714	2,187	2,823
Tax rate	31	25	25	25	25
Profit after tax	2,438	3,857	5,095	6,503	8,391

# **Balance Sheet**

Y/E Year End (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity	10,534	11,393	11,393	11,393	11,393
Reserves	16,796	22,459	27,665	34,168	42,559
Net worth	27,330	33,851	39,058	45,561	53,952
Deposits	107,884	163,920	210,254	276,092	352,854
Borrowings	49,149	41,653	37,488	35,613	33,833
Total liabilities	193,145	247,152	294,738	369,381	457,945
Cash and bank	3,809	5,148	5,405	5,676	5,960
Investments	23,425	37,052	47,571	59,824	74,191
Loans	137,472	168,479	210,966	274,650	343,560
Others	4,751	5,984	6,800	7,730	8,796
Total assets	193,145	247,152	294,738	369,381	457,945

# Key Ratios (%)

FY20	FY21	FY22E	FY23E	FY24E
9.0	8.5	8.6	8.4	8.3
1.6	1.9	1.6	1.4	1.3
0.1	0.7	0.7	0.7	0.6
6.7	6.0	5.7	5.5	5.3
1.4	1.7	1.6	1.4	1.3
2.0	2.3	2.5	2.6	2.7
0.6	0.6	0.6	0.7	0.7
1.4	1.8	1.9	2.0	2.0
9.8	12.6	14.0	15.4	16.9
3.0	3.7	3.4	2.9	2.6
1.8	1.6	1.4	1.0	0.8
FY20	FY21	FY22E	FY23E	FY24E
2.4	3.5	4.5	5.7	7.4
26.5	30.9	34.3	40.0	47.4
20.0	00.0			
24.7	29.1	32.4	38.1	45.6
24.7	29.1	32.4	38.1	45.6 0.0
24.7	29.1	32.4	38.1	
24.7 0.0	29.1 0.0	32.4 0.0	38.1 0.0	0.0
24.7 0.0 <b>FY20</b>	29.1 0.0 FY21	32.4 0.0 <b>FY22E</b>	38.1 0.0 <b>FY23E</b>	0.0 <b>FY24E</b> 7.5
24.7 0.0 <b>FY20</b> 23.4	29.1 0.0 <b>FY21</b> 15.8	32.4 0.0 <b>FY22E</b> 12.4	38.1 0.0 <b>FY23E</b> 9.7	0.0 <b>FY24E</b> 7.5 1.2
24.7 0.0 <b>FY20</b> 23.4 2.2	29.1 0.0 <b>FY21</b> 15.8 1.9	32.4 0.0 <b>FY22E</b> 12.4 1.7	38.1 0.0 <b>FY23E</b> 9.7 1.5	0.0 <b>FY24E</b>
	9.0 1.6 0.1 6.7 1.4 2.0 0.6 1.4 9.8 3.0 1.8 FY20 2.4	9.0 8.5   1.6 1.9   0.1 0.7   6.7 6.0   1.4 1.7   2.0 2.3   0.6 0.6   1.4 1.8   9.8 12.6   3.0 3.7   1.8 1.6   FY20   FY21   2.4 3.5	9.0 8.5 8.6   1.6 1.9 1.6   0.1 0.7 0.7   6.7 6.0 5.7   1.4 1.7 1.6   2.0 2.3 2.5   0.6 0.6 0.6   1.4 1.8 1.9   9.8 12.6 14.0   3.0 3.7 3.4   1.8 1.6 1.4   FY20   FY21 FY22E   2.4 3.5 4.5	9.0 8.5 8.6 8.4   1.6 1.9 1.6 1.4   0.1 0.7 0.7 0.7   6.7 6.0 5.7 5.5   1.4 1.7 1.6 1.4   2.0 2.3 2.5 2.6   0.6 0.6 0.6 0.7   1.4 1.8 1.9 2.0   9.8 12.6 14.0 15.4   3.0 3.7 3.4 2.9   1.8 1.6 1.4 1.0

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

India Equity Research | Result Update

11.7

4.7

12.8

4.2

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
NII	29.8	20.2	23.9	20.7	24.0
PPOP	40.2	48.9	26.1	20.1	24.1
PAT	15.8	58.2	32.1	27.6	29.0
Loans	18.6	22.6	0.0	0.0	0.0

Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
NII	4,239	4,040	4,612	4,839	4,486
NIM(%)	9.1	8.6	9.0	8.5	7.6
PPOP	1,884	1,460	2,197	2,750	2,498
PAT	431	600	1,030	1,107	1,129
EPS (Rs)	0.41	0.57	0.98	0.97	0.99
Source: Company, Emkay Research					
Shareholding Pattern (%)				Dec-20	Nov-21
Promoters				82.1	81.9
FIIs				1.5	1.02

DIIs Public and Others

Source: Capitaline

# RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
29-Jan-21	39	52	12m	Buy	Anand Dama
20-Jan-21	41	52	12m	Buy	Anand Dama
11-Nov-20	33	42	12m	Buy	Anand Dama

**RECOMMENDATION HISTORY CHART** 



Source: Company, Emkay Research

Source: Bloomberg, Company, Emkay Research

Analyst: Anand Dama

anand.dama@emkayglobal.com

Anand Dama is a CA, CPM (ICFAI) with

total 12 years of research experience, in

addition to 3 years in the finance/rating

industry. His team currently covers 21

stocks in

the

15

**Contact Details** 

+91 22 6624 2480

and

NBFC/Insurance space.

Sector Banks Analyst bio

banks

# Emkay Alpha Portfolio – BFSI-Banks

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
BFSI-Banks	20.98	20.95	-0.1%	-3	100.00
Axis Bank	2.22	2.31	4%	9	11.00
AU Small Finance Bank	0.29	0.25	-13%	-4	1.19
Bandhan Bank	0.28	0.33	18%	5	1.59
Bank of Baroda	0.15	0.10	-31%	-5	0.50
Canara Bank	0.09	0.00	-100%	-9	0.00
City Union Bank	0.15	0.22	48%	7	1.05
DCB Bank	0.00	0.00	NA	0	0.00
Equitas Small Finance Bank	0.00	0.00	NA	0	0.00
Federal Bank	0.18	0.23	23%	4	1.09
HDFC Bank	7.16	7.29	2%	13	34.73
ICICI Bank	5.11	5.26	3%	15	25.08
Indian Bank	0.00	0.00	NA	0	0.00
Indusind Bank	0.63	0.71	13%	8	3.38
Karur Vysya Bank	0.00	0.00	NA	0	0.00
Kotak Mahindra Bank	2.82	2.32	-18%	-50	11.08
Punjab National Bank	0.10	0.00	-100%	-10	0.00
RBL Bank	0.12	0.12	0%	0	0.55
State Bank of India	1.66	1.81	9%	15	8.62
Ujjivan Small Finance Bank	0.00	0.00	NA	0	0.00
Union Bank of India	0.03	0.00	-100%	-3	0.00
Yes Bank	0.00	0.00	NA	0	0.00
Cash	0.00	0.03	NA	3	0.15

Source: Emkay Research

\* Not under coverage: Equal Weight

High Conviction/Strong Over Weight High Conviction/Strong Under Weight

### Sector portfolio NAV


	Base					Latest
	01-Apr-19	29-Apr-20	28-Oct-20	27-Jan-21	26-Mar-21	28-Apr-21
EAP - BFSI-Banks	100.0	72.9	84.7	104.1	113.8	115.7
BSE200 Neutral Weighted Portfolio (ETF)	100.0	72.0	83.4	102.4	111.6	113.5

\*Performance measurement base date 1<sup>st</sup> April 2019 Source: Emkay Research

# Price Performance (%)

	1m	3m	6m	12m
EAP - BFSI-Banks	1.7%	11.1%	36.7%	58.7%
BSE200 Neutral Weighted Portfolio (ETF)	1.7%	10.8%	36.0%	57.6%
Source: Emkay Research				

## NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMIKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 01 May 2021 19:33:54 (SGT) Dissemination Date: 01 May 2021 19:34:54 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

# COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 1, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 1, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 1, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 1, 2021

RESTRICTIONS ON D	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

# Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com